Select a Region North America

Overcoming the Commercialization Challenges of Personalized Cancer Immunotherapies

Personalized cancer immunotherapies are emerging as a revolutionary approach to cancer treatment, aiming to provide individualized therapies based on a patient’s specific genetic makeup. The FDA has not yet approved any personalized cancer immunotherapies, creating an intense race within pharma to be the first mover.  

These therapies have the potential to overcome the limitations of conventional treatments and show efficacy across different patient populations. However, commercializing these therapies poses challenges related to pricing, turnaround times, manufacturability, scalability, and patient access.  

Despite the enormous opportunities personalized cancer immunotherapies present, there are several challenges to overcome: 

  • Manufacturing and administration processes differ from traditional therapies, requiring improvements in production efficiency and ease of administration.  
  • Personalized immunotherapies rely on next generation sequencing to identify neoantigens, creating access and affordability issues in underserved communities.  
  • Technological and regulatory hurdles, as well as the need to prove value for reimbursement and adoption, further complicate commercialization efforts.  

To address these challenges, manufacturers must: 

  • Adopt innovative commercialization models,  
  • Migrate their supply chain and data processing,  
  • Develop unique strategies for premarket education, cost management, and patient services programs. 

Download the full white paper now. 

Author
Anne Marie Robertson
Executive Vice President, EVERSANA ONCOLOGY Commercialization™

Anne Marie is helping EVERSANA deliver value to stakeholders across the life sciences industry. Through her multi-decade career at prominent large and small pharmaceutical companies, she has become a proven biopharma leader driving cross-functional…

Maneesh Gupta
Senior Partner

Maneesh comes to EVERSANA Management Consulting from IQVIA. He held a number of leadership roles over his 10 years at the firm, most recently serving as Practice Lead, Launch Excellence and Brand and Commercial…